Summary of publications
Peer–reviewed papers
([x] indicates number of citations received)
1991
1
Taylor D, Tunstell P. Metered dose inhalers: A system for assessing technique in
patients and health professionals. Pharmaceutical Journal 1991; 246: 626-627. [11]
2
Gore R, Taylor D, Porteous M, Flowers M, Wharton R. Topical phenytoin.
Pharmaceutical Journal 1991; 247:620 (letter). [0]
3
Taylor DM, Flowers MK. Variable theophylline clearance in cystic fibrosis. Annals of
Pharmacotherapy 1991; 25: 212 (letter). [2]
1993
4
Helliwell M, Taylor D.
An in-vitro evaluation of some dry cough preparations.
Pharmaceutical Journal 1993; 251:711-713. [0]
5
Taylor DM, Massey CA, Willson WG, Dhillon S. Lowered serum phenytoin
concentrations
during
therapy
with
liquid
food
concentrates.
Annals
of
Pharmacotherapy 1993;27:369 (letter). [2]
1995
6
Duncan D, Taylor D. Which is the safest antidepressant to use in epilepsy?
Psychiatric Bulletin 1995;19:355-356. [11]
7
Taylor D. Clozapine - five years on. Pharmaceutical Journal 1995; 254: 260-263. [3]
8
Duncan D, Taylor D.
Which antidepressants are safe to use in breast-feeding
mothers? Psychiatric Bulletin 1995;19:551-552. [4]
9
Duncan D, Taylor D. Treatment of psychotropic-induced hyperprolactinaemia.
Psychiatric Bulletin. 1995;19:755-757. [4]
10
Taylor D, Branford D, Bazire S, Donoghue J, Day J, Haygarth L. Community Care:
Pharmaceutical care for people with enduring mental health needs.
Pharmaceutical
Journal 1995; 255: 501-503. [2]
11
Taylor D, Duncan D. Plasma levels of tricyclics and related antidepressants: are they
necessary or useful? Psychiatric Bulletin 1995;19:548-550. [3]
12
Taylor D, Duncan D. The use of clozapine plasma levels in optimising therapy.
Psychiatric Bulletin 1995;19:753-755. [2]
13
Taylor D. Selective Serotonin Reuptake Inhibitors and tricyclic antidepressants in
combination - interactions and therapeutic uses. British Journal of Psychiatry
1995;167:575-580. [41]
14
Taylor D, Reveley A, Faivre F. Clozapine-induced hypotension treated with
moclobemide and Bovril. British Journal of Psychiatry 1995;167:409-410 (letter). [5]
1996
15
Duncan D, Taylor D. Treatment of psychosis in Parkinson’s disease. Psychiatric
Bulletin 1996; 20:157-159. [1]
16
Kerwin R, Taylor D. New antipsychotics: a review of their current status and clinical
potential. CNS Drugs 1996;6: 71-82. [46]
17
Hilton T, Taylor D, Abel K. Which dose of haloperidol?. Psychiatric Bulletin 1996;
20:359-362. [3]
18
Ramuth S, Flannagan RJ, Taylor DM. A liquid clozapine preparation for oral
administration in hospital. Pharmaceutical Journal 1996; 257:190-191. [3]
19
Taylor D, Duncan D. Treatment options for rapid-cycling bipolar affective disorder.
Psychiatric Bulletin 1996; 20:601-603. [2]
20
Duncan D, Taylor D. Chlormethiazole or chlordiazepoxide in alcohol detoxification.
Psychiatric Bulletin 1996; 20:599-601. [9]
21
Taylor D, Lader M. Cytochromes and psychotropic drug interactions. British Journal
of Psychiatry 1996;168:529-532. [30]
1997
22
McAskill R, Taylor D. Psychotropics and hyponatraemia. Psychiatric Bulletin 1997;
21:33-35. [3]
23
Mir S, Taylor D.
The adverse effects of antidepressants.
Current Opinion in
Psychiatry 1997; 10:88-94. [28]
24
Taylor D, Duncan D. Doses of carbamazepine and valproate in bipolar affective
disorder. Psychiatric Bulletin 1997; 21: 221-223. [7]
25
Duncan D, McConnell H, Taylor D. Tardive dyskinesia – how is it prevented and
treated? Psychiatric Bulletin 1997; 21: 422-425. [4]
26
Kerr I, Taylor D.
Acute disturbed or violent behaviour: principles of treatment.
Journal of Psychopharmacology 1997; 11: 271-277. [28]
27
McConnell H, Duncan D, Taylor D. Choice of neuroleptics in epilepsy. Psychiatric
Bulletin 1997; 21: 642-645. [3]
28
Taylor D. Pharmacokinetic interactions involving clozapine.
British Journal of
Psychiatry 1997; 171: 109-112. [56]
29
Taylor D, Holmes R, Hilton T, Paton C. Evaluating and improving the quality of
risperidone prescribing. Psychiatric Bulletin 1997; 21: 680-683. [12]
30
Taylor D. Switching from typical to atypical antipsychotics. CNS Drugs 1997; 8:
285-292. [15]
31
Kerr I B, Taylor D. Caution is needed with rapid tranquillisation protocol. British
Medical Journal. 1997; 315: 885 (letter). [3]
32
Taylor D. Establishing cost-effectiveness of antipsychotic drugs. British Journal of
Psychiatry 1997; 171: 486 (letter). [2]
1998
33
Duncan D, Sayal K, McConnell H, Taylor D.
Antidepressant interactions with
warfarin. International Clinical Psychopharmacology 1998; 13: 87-94. [38]
34
Mir S, Taylor D.
Sexual adverse effects with new antidepressants.
Psychiatric
Bulletin 1998; 22:438-441. [7]
35
McAskill R, Mir S, Taylor D. Pindolol augmentation of antidepressant therapy. British
Journal of Psychiatry 1998; 173: 203-208. [68]
36
Taylor D, Ellison, Z, Ementon Shaw L, Wickham H, Murray R. Co-administration of
citalopram and clozapine: effect on plasma clozapine levels. International Clinical
Psychopharmacology 1998; 13: 19-21. [27]
37
Mir S, Taylor D. Current issues in the treatment of schizophrenia. Pharmaceutical
Journal 1998; 261: 55-58. [0]
38
Taylor D, Drummond S, Pendlebury J. Olanzapine in practice. Psychiatric Bulletin
1998; 22: 552-554. [14]
39
Duncan D, McConnell H W, Taylor D.
Psychiatric Bulletin 1998; 22: 630-632. [0]
Lamotrigine in bipolar affective disorder.
1999
40
Malhi G S, Holloway F, Taylor D. Zuclopenthixol acetate (Clopixol Acuphase) for
rapid sedation. International Journal of Psychiatry in Clinical Practice 1999; 3: 135136 (letter). [3]
41
Taylor D. Bodani M, Hubbeling A, Murray R. The effect of nefazodone on clozapine
plasma concentrations. International Clinical Psychopharmacology 1999; 14: 185-7.
[24]
42
Taylor D, Aitchison K J.
The pharmaco-economics of atypical antipsychotics.
International Journal of Psychiatry in Clinical Practice 1999; 3: 237-248. [12]
43
Taylor D, Mir S, Mace S. Olanzapine in practice: a prospective naturalistic study.
Psychiatric Bulletin 1999; 23: 178-180. [3]
44
Taylor DM. Pharmacoeconomics of atypical antipsychotics. Journal of Advances in
Schizophrenia and Brain Research 1999; 2: 2-7. [0]
45
Taylor D. Depot antipsychotics revisited. Psychiatric Bulletin 1999; 23: 551-553. [6]
46
Taylor D, Kerr I. Rapid tranquillisation in isolated units, i.m. medication preferable to
i.v. Journal of Psychopharmacology 1999; 13: 201-202 (letter). [1]
47
Mir S, Taylor D. Serotonin syndrome. Psychiatric Bulletin 1999; 23: 742-747. [2]
48
Taylor D. Refractory schizophrenia: evidence-based treatment. Pharmaceutical
Journal 1999; 263, Suppl: 2-3. [6]
2000
49
Taylor DM, Starkey K, Ginary S. Prescribing and monitoring of carbamazepine and
valproate - a case note review. Psychiatric Bulletin 2000; 24: 174-177. [9]
50
Taylor D, Mir S, Kerwin R. Prescribing in schizophrenia: evaluating the effect of
introducing a new treatment protocol. Psychiatric Bulletin 2000; 24: 106-108. [14]
51
Harvey E, Flanagan R, Taylor D. The preparation and stability of a liquid olanzapine
preparation
for
oral
administration
in
hospitals.
Pharmaceutical
Journal
2000;265;275-277. [5]
52
Taylor D, Shapland L, Laverick G, et al. Clozapine – a survey of patient perceptions.
Psychiatric Bulletin 2000; 24:450-452. [10]
53
Mace S, Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and
tolerability in depression. Expert Opinion in Pharmacotherapy 2000; 1: 917-933.
[43]
54
Taylor D. Low dose typical antipsychotics – a brief evaluation. Psychiatric Bulletin
2000; 24: 465-468. [7]
55
Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Safety, 2000:
22; 195-214. [112]
56
Taylor D, Mace S, Mir S, Kerwin R. A prescription survey of the use of atypical
antipsychotics for hospital inpatients in the United Kingdom. International Journal of
Psychiatry in Clinical Practice 2000; 4: 41-46. [33]
57
Donoghue J, Taylor D.
Suboptimal use of antidepressants in the treatment of
depression. CNS Drugs 2000; 13: 365-383. [24]
58
Taylor D, McAskill R. Atypical antipsychotics and weight gain – a systematic review.
Acta Psychiatrica Scandinavica 2000; 101: 416-432. [336]
59
Butler JA, Taylor D.
A survey of lithium monitoring and prescribing patterns.
International Journal of Psychiatry in Clinical Practice 2000; 4: 135-138. [2]
60
Sayal KS, Duncan-McConnell DA, McConnell HW, Taylor DM. Psychotropic
interactions with warfarin. Acta Psychiatrica Scandinavica 2000; 102: 250-255. [46]
61
Taylor
D,
Duncan-McConnell
D.
Refractory
schizophrenia
and
atypical
antipsychotics. Journal of Psychopharmacology 2000, 14, 409-418. [48]
2001
62
Kumari V, Zachariah E, Galea A, Mehrotra R, Taylor D, Sharma T.
Effects of
procyclidine on prepulse inhibition of the acoustic startle response in healthy human
volunteers. Psychopharmacology 2001; 154: 221-229. [22]
63
Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. International Clinical
Psychopharmacology 2001; 16: 63-73. [134]
64
Whiskey E, Werneke U, Taylor D.
A systematic review and meta-analysis of
Hypericum perforatum in depression: a comprehensive clinical review. International
Clinical Psychopharmacology, 2001; 16: 239-252. [116]
65
Taylor D, Mace S, Fry C. The use of anticholinesterases for Alzheimer’s disease in
Britain. Pharmaceutical Journal 2001; 266: 263. [4]
66
Taylor D. Pragmatic considerations are important when considering which drug to
prescribe. British Medical Journal 2001; 322: 925 (letter). [3]
67
Taylor D. Ziprasidone – an atypical antipsychotic. Pharmaceutical Journal 2001;
266: 396-401. [3]
68
Taylor D, Mace S, Young C.
Health Authority adherence to prescribing-related
requirements of the NSF in Mental Health. Pharmaceutical Journal 2001; 267: 753754. [0]
69
Harvey EJ, Taylor DM, Flanagan RJ. D2 receptor occupancy under recommended
and high doses of olanzapine. Journal of Psychopharmacology, 2001; 15: 213-214
(letter). [4]
2002
70
Sharma T, Galea A, Zachariah E, Das M, Taylor D, Ruprah M, Kumari V. Effects of
10 mg and 15 mg oral procyclidine on critical flicker fusion threshold and cardiac
functioning in healthy human subjects. Journal of Psychopharmacology, 2002; 16:
181-185. [7]
71
Werneke U, Taylor D, Sanders TAB. Options for pharmacological management of
obesity in patients treated with atypical antipsychotics.
International Clinical
Psychopharmacology, 2002; 17; 145. [76]
72
Stone J, Ohlsen R, Taylor D et al. Naturalistic study of the antipsychotic medication
review service at the Maudsley Hospital. Psychiatric Bulletin 2002; 26: 291-294. [3]
73
Zachariah E, Kumari V, Galea A, Das M, Mehrotra R, Taylor D, Ruprah M, Sharma
T. Effects of oral procyclidine administration on cognitive functions in healthy
volunteers. Journal of Clinical Psychopharmacology 2002; 22:224-226. [17]
74
Taylor D, Mir S, Mace S, Whiskey E.
Co-prescribing of atypical and typical
antipsychotics prescribing sequence and documented outcome. Psychiatric Bulletin
2002; 26:170-172. [28]
75
Taylor D. Antipsychotic prescribing – time to review practice. Psychiatric Bulletin
2002; 26: 401-402. [14]
76
Coker-Adeyemi F, Taylor D.
Clozapine plasma levels in patients switched from
clozapine liquid to tablets. Pharmaceutical Journal 2002; 269: 650-652. [1]
77
Mace S, Taylor D. Adherence to NICE guidance for the use of anticholinesterases
for Alzheimer’s disease. Pharmaceutical Journal 2002; 269: 680-681. [8]
78
Taylor DM. Prolongation of the QTc interval and antipsychotics. American Journal of
Psychiatry, 2002; 6; 1062 (letter). [6]
2003
79
Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently
receiving clozapine – a case note review. Journal of Clinical Psychiatry 2003; 64: 3039. [43]
80
Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatrica Scandinavica
2003; 107: 85-95. [107]
81
Taylor DM. Aripiprazole: A review of its pharmacology and clinical use. International
Journal of Clinical Practice 2003; 57: 49-53. [54]
82
Ettinger U, Kumari V, Zachariah E, Galea A, Crawford TJ, Corr PJ, Taylor D, Das M,
Sharma T.
Effects of procyclidine on eye movements in schizophrenia.
Neuropsychopharmacology, 2003; 28: 2199-2208. [29]
83
Kumari V, Zachariah E, Galea A, Jones HC, Das M, Mehrotra R, Taylor D, Sharma
T. Effects of acute procyclidine administration on prepulse inhibition of the startle
response in schizophrenia: a double-blind, placebo-controlled study.
Journal of
Psychopharmacology, 2003; 17: 89-95. [30]
84
Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in
context. CNS Drugs, 2003; 17: 423-430. [70]
85
Taylor DM, Wright T, Libretto SE. Risperidone compared with olanzapine in a
naturalistic clinical study – a cost analysis. Journal of Clinical Psychiatry, 2003; 64:
589 – 597. [16]
86
Bokszanska A, Martin G, Vanstraelen M, Holt G, Bouras N, Taylor D. Risperidone
and olanzapine in adults with intellectual disability: a clinical naturalistic study.
International Clinical Psychopharmacology, 2003;18:285-291. [13]
87
Werneke U, Taylor D, Sanders TAB, Wessely S. Behavioural management of
antipsychotic-induced weight gain: a review. Acta Psychiatrica Scandinavica 2003;
108:252-259. [40]
88
Thomas A, Taylor D.
Evaluating the relationship of high-dose venlafaxine
prescribing to treatment-resistant depression. Psychiatric Bulletin 2003; 27: 93-95.
[4]
2004
89
Patel MX, Young C, Samele C, Taylor DM and David AS. Prognostic indicators for
early discontinuation of risperidone long-acting injection.
International Clinical
Psychopharmacology 2004; 19:233-239. [12]
90
Werneke U, Horn O, Taylor DM. How effective is St. John’s Wort? The evidence
revisited. Journal of Clinical Psychiatry 2004; 65:611-617. [50]
91
Taylor DM. Prescribing of clozapine and olanzapine: dosage, polypharmacy and
patient ethnicity. Psychiatric Bulletin 2004; 28:241-243. [11]
92
Taylor DM, Young CL, Mace S and Patel MX.
Early clinical experience with
risperidone long-acting injection: A prospective, 6-month follow-up of 100 Patients.
Journal of Clinical Psychiatry 2004; 65:1076-1083. [39]
93
Taylor DM, Young C, Esop R, Paton C, Walwyn R. Testing for diabetes in
hospitalised patients prescribed antipsychotic drugs. British Journal of Psychiatry
2004; 185:152-156. [60]
94
Paton C, Esop R, Young C, Taylor D. Obesity, dyslipidaemias and smoking in an
inpatient
population
treated
with
antipsychotic
drugs.
Acta
Psychiatrica
Scandinavica 2004; 110:299-305. [70]
95
Nuss P, Taylor D, De Hert M and Hummer M.
The generic alternative in
schizophrenia. CNS Drugs 2004; 18:769-775. [11]
96
Whiskey E, Taylor D. Pramipexole in unipolar and bipolar depression. Psychiatric
Bulletin 2004, 28, 438-440. [5]
2005
97
Taylor D, Young C, Mohamed R, Paton C, Walwyn R..
Undiagnosed impaired
fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic
drugs. Journal of Psychopharmacology 2005; 19: 182-186. [40]
98
Travis MJ, Burns T, Dursun T, Fahy T, Frangou S, Gray R, Haddad PM, Hunter R,
Taylor DM, Young AH.
Aripiprazole in schizophrenia: consensus guidelines.
International Journal of Clinical Practice 2005; 59: 485-495. [30]
99
Taylor D.
Psychotropic drugs, torsade de pointes and sudden death.
Acta
Psychiatrica Scandinavica 2005; 111: 169-170. [3]
100
Taylor D.
Establishing a dose-response relationship for haloperidol decanoate.
Psychiatric Bulletin 2005; 29: 104-107. [6]
101
Mace S and Taylor D. A prescription survey of antipsychotic use in England and
Wales following the introduction of NICE guidance.
International Journal of
Psychiatry in Clinical Practice 2005; 9: 124-129. [6]
102
Olofinjana B and Taylor D. Antipsychotic drugs – information and choice: a patient
survey. Psychiatric Bulletin 2005; 29: 369-371. [13]
103
Spencer EP, Morgan PE, Flanagan RJ, Taylor D. Plasma olanzapine concentrations
in clinical practice: UK experience. Therapeutic Drug Monitoring 2005; 27: 226-227.
[0]
104
Whiskey E and Taylor D.
Evaluation of an antipsychotic information sheet for
patients. International Journal of Psychiatry in Clinical Practice 2005; 9: 264-270.
[2]
2006
105
Ezewuzie N and Taylor D.
Establishing a dose-response relationship for oral
risperidone in relapse schizophrenia. Journal of Psychopharmacology 2006; 20: 8690. [24]
106
Stubbs J, Haw C, Taylor D. Prescription errors in psychiatry – a multi-centre study.
Journal of Psychopharmacology 2006; 20: 533-561. [25]
107
Young CL and Taylor DM. Health resource utilization associated with switching to
risperidone long-acting injection. Acta Psychiatrica Scandinavica 2006; 114: 14-20.
[28]
108
Taylor D.
Risperidone long-acting injection in practice – more questions than
answers? Acta Psychiatrica Scandinavica 2006; 114: 1-2. [9]
109
Luft B, Taylor D.
A review of atypical antipsychotic drugs versus conventional
medication in schizophrenia. Expert Opinion in Pharmacotherapy 2006; 7: 17391748. [25]
110
Taylor D, Scott JR. Volte-face on venlafaxine – reasons and reflections Journal of
Psychopharmacology 2006; 20: 597-601. [1]
111
Taylor D, Stewart S, Connolly A. Antidepressant withdrawal symptoms – Telephone
calls to a national helpline. Journal of Affective Disorders 2006; 95: 129-133. [12]
112
Taylor DM, Young C, Patel MX. Prospective 6-month follow-up of patients
prescribed risperidone long-acting injection: factors predicting favourable outcome.
International Journal of Neuropsychopharmacology 2006; 9: 685-694. [30]
113
Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D,
Hayhurst KP, Markwick A, Lloyd H, Dunn G.
Randomised controlled trials of
conventional antipsychotic versus new atypical drugs, and new atypical drugs versus
clozapine, in people with schizophrenia responding poorly to, or intolerant of, current
drug treatment. Health Technology Assessment 2006; 10: 1-165. [57]
2007
114
Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Acute bipolar mania: a
systematic review and meta-analysis of co-therapy vs. monotherapy.
Psychiatrica Scandinavica 2007; 115: 12-20. [54]
Acta
115
Whiskey E and Taylor D. Restarting clozapine after neutropenia. CNS Drugs 2007;
21: 25-35. [26]
116
Orr K and Taylor D. Psychostimulants in the treatment of depression. CNS Drugs
2007; 21: 239-257. [28]
117
Bleakley S, Olofinjana O and Taylor D. Which antipsychotics would mental health
professionals take themselves? Psychiatric Bulletin 2007; 31: 94-96. [8]
118
Connolly A, Rogers P and Taylor D. Antipsychotic prescribing quality and ethnicity –
a study of hospitalized patients in South East London. Journal of
Psychopharmacology 2007; 21: 191-197. [9]
119
Taylor D, Hayhurst K, Kerwin R.
A controlled, mirror-image study of second-
generation antipsychotics in the treatment of schizophrenia. International Clinical
Psychopharmacology 2007; 22: 133-136. [1]
120
Sullivan G, Bienroth M, Jones M, Millar H, Ratna L, Taylor D. Practical prescribing
with aripiprazole in schizophrenia: Consensus recommendations of a UK
multidisciplinary panel. Current Medical Research and Opinion 2007; 23:1733-1744.
[12]
121
Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H,
Peveler R, Rees A, Singh V, Taylor D, Vora J, Jones PB. Minimising metabolic and
cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. Journal of
Psychopharmacology 2007; 21: 357-373. [94]
122
Atkinson JA, Douglas-Hall P, Sparshatt A, Fischetti C, Taylor D. Outcome following
clozapine discontinuation: a retrospective analysis. Journal of Clinical Psychiatry
2007; 68: 1027-1030. [8]
123
Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D.
Pharmacological
interventions for acute bipolar mania: a systematic review of randomized placebocontrolled trials. Bipolar Disorders 2007; 9: 551-560. [60]
124
Taylor D, Atkinson J, Fischetti C, Sparshatt A, Jones A. A prospective 6-month
analysis of the naturalistic use of aripiprazole – factors predicting favourable
outcome. Acta Psychiatrica Scandinavica 2007; 116: 461-466. [6]
125
Barnes TRE, Paton C, Cavanagh MR, Hancock E, Taylor DM.
A UK audit of
screening for the metabolic side effects of antipsychotics in community patients.
Schizophrenia Bulletin 2007; 33: 1397-1403. [75]
126
James L, Barnes TRE, Lelliott P, Taylor D, Paton C.
Informing patients of the
teratogenic potential of mood stabilizing drugs: a case note review of the practice of
psychiatrists. Journal of Psychopharmacology 2007; 21: 815-819. [9]
2008
127
Sparshatt A, Jones S, Taylor D.
Quetiapine.
Dose-response relationship in
schizophrenia. CNS Drugs 2008; 22: 49-68. [27]
128
Attard A, McRobbie D, Taylor D, West T.
A career as a psychiatric liaison
pharmacist. Hospital Pharmacist 2008; 15: 99-100. [0]
129
Paton C, Barnes TRE, Cavanagh MR, Taylor D, Lelliott P.
High-dose and
combination antipsychotic prescribing in acute adult wards in the UK: the challenges
posed by p.r.n. prescribing. British Journal of Psychiatry 2008; 192: 435-439. [32]
130
Barnes TRE, Paton C, Hancock E, Cavanagh M-R, Taylor D, Lelliot P. Screening for
metabolic syndrome in community psychiatric patients prescribed antipsychotics: a
quality improvement programme. Acta Psychiatrica Scandinavica 2008; 118:26-33.
[22]
131
Sparshatt A, Whiskey E, Taylor D. Valproate as prophylaxis for clozapine-induced
seizures: survey of practice. Psychiatric Bulletin 2008; 32: 262-265. [2]
132
Attard A, Ranjith G, Taylor D. Delirium and its treatment. CNS Drugs 2008; 22: 631644. [8]
133
Connolly A and Taylor D. Ethnicity and quality of antipsychotic prescribing among in-
patients in South London. British Journal of Psychiatry 2008; 193: 161-162. [7]
134
Taylor D, Hanssens L, Loze JY, Pans M, L’Italien G, Marcus RN. Preference of
medicine and patient-reported quality of life in community-treated schizophrenic
patients receiving aripiprazole vs standard of care: results from the STAR study.
European Psychiatry 2008; 23: 336-343. [8]
135
Douglas-Hall P and Taylor D. Lithium monitoring in community psychiatric patients.
Progress in Neurology and Psychiatry 2008; Suppl 1, 2-7. [0]
136
Bishara D and Taylor D.
Upcoming agents for the treatment of schizophrenia.
Drugs 2008; 68: 2269-2292. [55]
137
Taylor D, Okocha C, Paton C, Smith S and Connolly A.
Buccal midazolam for
agitation on psychiatric intensive care wards. International Journal of Psychiatry in
Clinical Practice 2008; 12: 309-311. [1]
138
Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of
effectiveness and safety. Acta Psychiatrica Scandinavica 2008; 118: 434-442. [41]
139
McCrone P, Aitchison, KJ and Taylor D.
pharmacoeconomics
for
psychiatry
and
where
How far have we got in
are
we
going?
Clinical
Neuropsychiatry 2008; 5: 173-174. [1]
140
Ohlsen RI, Taylor D, Tandon K, Aitchison, KJ. Returning to the issue of the costeffectiveness of antipsychotics in the treatment of schizophrenia.
Clinical
Neuropsychiatry 2008; 5: 184-194. [3]
2009
141
Taylor DM. Withdrawal of rimonabant – walking the tightrope of 21st century
pharmaceutical regulation? Current Drug Safety 2009; 4: 2-4. [9]
142
Taylor DM, Douglas-Hall P, Olofinjana B, Whiskey E and Thomas A. Reasons for
discontinuing clozapine: matched, case-control comparison with risperidone longacting injection. British Journal of Psychiatry 2009; 194: 165-167. [15]
143
Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D and Cornelius V.
Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical
practice. Journal of Clinical Psychiatry 2009; 70: 196-200. [22]
144
Taylor D.M. Olanzapine pamoate – blockbuster or damp squib? International Journal
of Clinical Practice 2009; 63: 540-541. [4]
145
James L, Paton C, Lelliott P, Barnes TRE and Taylor D.
Mood stabilizers and
teratogenicity – prescribing practice and awareness amongst practising psychiatrists.
Journal of Mental Health 2009; 18: 137-143. [0]
146
Aitchison KJ, Bienroth M, Cookson J, Gray R, Haddad PM, Moore B, Ratna L,
Sullivan G, Taylor D, Taylor M, Goodwin GM. A UK consensus on the administration
of aripiprazole for the treatment of mania. Journal of Psychopharmacology 2009; 23:
231-240. [9]
147
Taylor DM and Smith, L. Augmentation of clozapine with a second antipsychotic – a
meta-analysis of randomized, placebo-controlled studies.
Acta Psychiatrica
Scandinavica 2009; 119: 419-425. [37]
148
Taylor D, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone
long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta
Psychiatrica Scandinavica 2009; 120: 97-101. [8]
149
Bishara D, Taylor D, Howard, R, Adbel-Tawab, R.
Expert opinion on the
management of behavioural and psychological symptoms of dementia (BPSD) and
investigation into prescribing practices in the UK. International Journal of Geriatric
Psychiatry 2009; 24: 994-954. [8]
150
Mace S and Taylor D. Aripiprazole. Dose-response relationship in schizophrenia
and schizoaffective disorder. CNS Drugs 2009; 23: 773-780. [11]
151
Bishara D and Taylor D. Asenapine monotherapy in the acute treatment of both
schizophrenia and bipolar I disorder. Neuropsychiatric Disease and Treatment 2009;
5: 483-490. [14]
152
Olofinjana O, Connolly A and Taylor D. Outcomes of information provision to callers
to a psychiatric medication helpline. Psychiatric Bulletin 2009; 33: 364-367. [0]
153
Taylor D.
Psychopharmacology and adverse effects of antipsychotic long-acting
injections: a review. British Journal of Psychiatry 2009; 195: S13-S19 [24]
154
Sparshatt A, Taylor D, Patel MX, Kapur S.
Amisulpride – dose, plasma
concentration, occupancy and response: implications for therapeutic drug monitoring.
Acta Psychiatrica Scandinavica 2009; 120: 416-428 [10]
2010
155
Taylor D. Antipsychotic polypharmacy – confusion reigns. The Psychiatrist 2010;
34: 41-43 [13]
156
Taylor D. Venlafaxine and cardiovascular toxicity. British Medical Journal 2010; 340:
327 [1]
157
Attard A, Ranjith G and Taylor D. Alternative routes to oral antidepressant therapy:
case vignette and literature review. Journal of Psychopharmacology 2010; 24: 449454 [2]
158
Coker F and Taylor D. Antidepressant-induced hyperprolactinaemia. Incidence,
mechanisms and management. CNS Drugs 2010; 24: 563-574 [2]
159
Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists’ attitude towards and
knowledge of clozapine treatment. Journal of Psychopharmacology 2010; 24: 965972 [20]
160
Taylor D and Cornelius V. Risperidone long-acting injections: factors associated with
changes in bed stay and hospitalisation in a 3-year naturalistic follow-up. . Journal
of Psychopharmacology 2010; 24: 995-1000 [3]
161
Taylor D, Olofinjana O, Rahimi T. Use of antacid medication in patients receiving
clozapine. A comparison with other second-generation antipsychotics. Journal of
Clinical Psychopharmacology 2010; 30: 460-461. [1]
162
Leonard B and Taylor D. Escitalopram – translating molecular properties into clinical
benefit: reviewing the evidence in major depression. Journal of
Psychopharmacology 2010; 24: 1143-1152. [1]
163
Howard LM. Barley EA, Davies E, Rigg A, Lempp H, Rose D, Taylor D, Thornicroft
G. Cancer diagnosis in people with severe mental illness: practical and ethical
issues. Lancet Oncology 2010; 11: 797-804. [15]
164
Deakin B, Ferrier N, Holt RIG, Millar H, Nutt DJ, Reynolds G, Samani N, Taylor D.
The physical health challenges in patients with severe mental illness: cardiovascular
and metabolic risks. Journal of Psychopharmacology 2010; 24 (suppl 1): 1-7. [1]
165
Holvey C, Connolly A, Taylor D. Psychiatric side effects of non-psychiatric drugs.
British Journal of Hospital Medicine 2010; 71: 432-436. [0]
166
Sparshatt A, Taylor D, Patel MX, Kapur S. A systematic review of aripiprazole –
dose, plasma concentration, receptor occupancy, and response: implications for
therapeutic drug monitoring. Journal of Clinical Psychiatry 2010; 71: 1447-1456 [15]
2011
167
Mace S, Taylor D.
Improving adherence to NICE guidance for bipolar illness:
valproate use in women of childbearing potential. The Psychiatrist 2011; 35: 63-67
[0]
168
Chaudhry IB, Rahman R, Minhas HM, Chaudhry N, Taylor D, Ansari M, Husain N.
Which antidepressant would psychiatrists and nurses from a developing country
choose for themselves? International Journal of Psychiatry in Clinical Practice 2011;
15: 74-78 [0]
169
Taylor D, Meader N, Bird V, Pilling S, Creed F, Goldberg D, the pharmacology
subgroup of the National Institute for Health and Clinical Excellence Guideline
Development Group for Depression in Chronic Physical Health Problems.
Pharmacological interventions for people with depression and chronic physical health
problems: systematic review and meta-analyses of safety and efficacy.
British
Journal of Psychiatry 2011; 198: 179-188 [9]
170
Whiskey E, Vavrova, M, Gaughran F, Taylor D. Melperone in treatment-refractory
schizophrenia: a case series. Therapeutic Advances in Psychopharmacology 2011;
1: 19-23 [0]
171
Bishara D and Taylor D. Paliperidone palmitate – a new long-acting injection for
schizophrenia. British Journal of Clinical Pharmacy 2011; 3: 75-78 [0]
172
Baldwin D, Woods R, Lawson R, Taylor D.
Efficacy of drug treatments for
generalised anxiety disorder: systematic review and meta-analysis. BMJ 2011; 342:
d1199 [21]
173
Douglas-Hall P, Curran S, Bird V, Taylor D. Aripiprazole: a review of its use in the
treatment of irritability associated with Autistic Disorder patients aged 6-17. Journal
of Central Nervous System Disease 2011; 3: 1-11 [0]
174
Nielsen J, Damkier P, Lublin H, Taylor D. Optimising clozapine treatment. Acta
Psychiatrica Scandinavia 2011; 123: 411-422 [21]
175
Connolly A, Taylor D, Sparshatt A, Cornelius V. Antipsychotic prescribing in black
and white hospitalised patients. Journal of Psychopharmacology 2011; 25: 704-709
[2]
176
Varma S, Bishara D, Besag FMC, Taylor D. Clozapine-related EEG changes and
seizures: dose and plasma-level relationships.
Psychopharmacology 2011; 1: 47-66 [4]
Therapeutic Advances in
177
Patel MX, Matonhodze J, Baig MK, Gilleen J, Boydell J, Holloway F, Taylor D,
Szmukler G, Lambert T, David AS.
injections
with
community
Increased use of antipsychotic long-acting
treatment
orders.
Therapeutic
Advances
in
Psychopharmacology 2011; 1: 37-45 [1]
178
Nielsen J, Graff C, Kanters J, Toft E, Taylor D, Meyer J. Assessing QT interval
prolongation and its associated risks with antipsychotics. CNS Drugs 2011; 25: 473490 [2]
179
Whiskey E, Olubanke O, Taylor D. The importance of the recognition of benign
ethnic neutropenia in black patients during treatment with clozapine: case reports
and database study. Journal of Psychopharmacology 2011; 25: 842-845 [2]
180
Patel MX, Bowskill S, Couchman L, Lay V, Taylor D, Spencer EP, Flanagan RJ.
Plasma olanzapine in relation to prescribed dose and other factors.
Journal of
Clinical Psychopharmacology 2011; 31: 411-417 [3]
181
Sparshatt A, Taylor D, Patel MX, Kapur S. Relationship between daily dose, plasma
concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a
review. Journal of Clinical Psychiatry 2011; 72: 1108-1123 [5]
182
Lloyd LC, Giaroli G, Taylor D, Tracy DK.
pharmacologically mismanaged.
Bipolar depression: clinically missed,
Therapeutic Advances in Psychopharmacology
2011; 1: 153-162 [0]
183
Bleakley S, Brown D, Taylor D.
Does clozapine cause or worsen obsessive
compulsive syndrome? An analysis and literature review. Therapeutic Advances in
Psychopharmacology 2011; 1: 181-188 [0]
184
Bishara D, Whiskey E, Taylor D. Asenapine: novel antipsychotic for treatment of
bipolar I disorder. Future Prescriber 2011; 12: 5- 8 [0]
185
Lyons M, Taylor D. Modern formulations of long-acting antipsychotics. Hospital
Pharmacy Europe 2011; 33-37 [0]
2012
186
Taylor DM, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a second
antipsychotic - a meta-analysis. Acta Psychiatrica Scandinavica 2012; 25: 15-24 [2]
187
Taylor M, Millar H, Cookson J, Carson J, MacDonald L, Currid T, Snowden A, Taylor
D. Perceptions on concordance with bipolar medication. British Journal of Hospital
Medicine 2012; Suppl: S2-S7. [0]
188
Chaudhry IB, Minhas HM, Rahman R, Husain MI, Taylor D, Ansari M, Husain N.
Which antipsychotic would mental health professionals from a low income country
choose for themselves? Journal of Pakistan Psychiatric Society 2012; 8: 79-83 [0]
189
Grech P, Taylor D. Long-term antipsychotic polypharmacy: how does it start, why
does it continue? Therapeutic Advances in Psychopharmacology 2012; 2: 5-11 [1]
190
Nielsen J, Emborg C, Gydesen S, Dybbro J, Aagaard J, Haderup K, Glyngdal P,
Fabricius S, Thode D, Lublin H, Andersen T, Damkier P, Taylor D. Augmenting
clozapine with sertindole.
A double-blind, randomised, placebo-controlled study.
Journal of Clinical Psychopharmacology 2012; 32: 173-178 [2]
191
Chang CK, Harrison S, Lee W, Taylor D, Stewart R.
Ascertaining instances of
neuroleptic malignant syndrome in a secondary mental healthcare electronic medical
records database: the SLAM BRC Case Register.
Therapeutic Advances in
Psychopharmacology 2012; 2: 75-83 [0]
192
Attard A and Taylor DM. Comparative effectiveness of atypical antipsychotics in
schizophrenia. What have real-world trials taught us? CNS Drugs 2012; 26: 491508 [0]
193
Fisher DS, Handley SA, Flanagan RJ, Taylor DM.
Plasma concentrations of
quetiapine, n-desalkyquetiapine, o-desalkylquetiapine, 7-hydroxyquetiapine and
quetiapine sulfoxide in relation to quetiapine dose, formulation and other factors.
Therapeutic Drug Monitoring 2012; 34: 415-421 [0]
194
Fisher DS, Handley SA, Taylor D, Flanagan RJ. Measurement of quetiapine and
four quetiapine metabolites in human plasma by LC-MS/MS.
Biomedical
Chromatography 2012; 26: 1125-1132 [0]
195
Werneke U, Ott M, Renberg E, Taylor D, Stegmayr B. A decision analysis of longterm lithium treatment and the risk of renal failure. Acta Psychiatrica Scandinavica
2012; 126: 186-197 [0]
196
Dobbs RJ, Charlett A, Dobbs SM, Weller C, Iguodala O, Smee C, Bowthrope J,
Taylor D, Bjarnason IT. Towards defining a rigidity-associated pathogenic pathway
in idiopathic parkinsonism. Neurodegenerative Diseases 2012; 10: 183-186 [0]
197
Taylor D. Metformin for schizophrenia. Acta Psychiatrica Scandinavica 2012; 126:
233-234 [0]
198
Dobbs RJ, Charlett A, Dobbs SM, Weller C, Ibrahim MAA, Iguodala O, Smee C,
Plant JM, Lawson AJ, Taylor D, Bjarnason I. Leukocyte-subject counts in idiopathic
parkinsonism provide clues to a pathogenic pathway involving small intestinal
bacterial overgrowth. A surveillance study. Gut Pathogens 2012; 4: 12-27 [0]
199
Nielsen J, Roge R, Schjerning O, Sorensen HJ, Taylor D.
Geographical and
temporal variations in clozapine prescription for schizophrenia.
European
Neuropsychopharmacology 2012; 22: 818-824 [0]
200
Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the evidence of
clozapine's
anti-aggressive
effects.
International
Journal
of
Neuropsychopharmacology 2012; 15: 1351-1371. [0]
Total publications
Total citations
‘H’ index
200
3600
35